Press & Material News Releases

November 21, 2023

Medigene AG Announces Prioritization of Pipeline and Resource Allocation as well as Extension of Cash Runway  

November 4, 2023

Medigene presents new data for MDG2011 demonstrating capability to generate TCR-T therapies against mKRAS

November 2, 2023

Medigene AG to participate at upcoming conferences

October 26, 2023

Medigene Reports Financial Results and Corporate Update for Q3 2023

October 23, 2023

Medigene presents first pre-clinical data of optimal affinity TCR targeting mKRAS G12V combined with a PD1-41BB costimulatory switch protein showing enhanced and sustained tumor killing

October 16, 2023

Medigene to present new pre-clinical data for pipeline TCR-T therapies at the ESMO Congress 2023

September 27, 2023

Medigene AG Secures European Patent for its PD1-41BB Costimulatory Switch Protein

September 18, 2023

Medigene AG Announces Lead Selection for MDG2011 Representing the First TCR-T Therapy of its KRAS Library

September 11, 2023

Medigene AG to present at the Baader Investment Conference 2023

September 5, 2023

Medigene AG to present at the H.C. Wainwright 25th Annual Global Investment Conference

August 30, 2023

Medigene presents rationale for combining its 3S TCRs with enhancement tools as an approach to improve clinical outcomes

August 23, 2023

Medigene Expands Intellectual Property Rights for its Costimulatory Switch Proteins to Additional Immune Cell Types

August 22, 2023

Medigene AG to present at the 8th CAR-TCR Summit in Boston

August 17, 2023

Medigene Reports Second Quarter and Six Months 2023 Financial Results and Provides Corporate Update

August 16, 2023

Medigene to participate in the H.C. Wainwright Immune Cell Engager Virtual Conference

August 10, 2023

Medigene AG to report Second Quarter and Six Months 2023 Financial Results and Corporate Update on August 17, 2023

June 22, 2023

Medigene Presents Enhanced Tumor Cell Killing Effects upon Addition of PD1-41BB Switch Receptor to TCR-T Therapies

June 14, 2023

Medigene to Present at the Immuno-Oncology Summit Europe

June 13, 2023

Medigene to Host Virtual R&D Event on TCR-T Therapies for Solid Tumors

June 1, 2023

Medigene Announces Pipeline Expansion into Neoantigens with Programs Targeting Multiple KRAS Mutations and HLAs

May 30, 2023

Medigene AG to participate at BIO International in Boston

May 22, 2023

Medigene AG Expands Patent Portfolio for its End-to-End Platform

May 8, 2023

Medigene AG to present at upcoming investor conferences

May 4, 2023

Expitope 3.0 presented at CIMT enables more comprehensive analysis of target antigens for TCR-T therapies

May 3, 2023

Medigene AG reports financial results and business update for Q1 2023

May 2, 2023

Medigene acquires worldwide, exclusive license of CD40L-CD28 Costimulatory Switch Receptor

April 27, 2023

Medigene to Present Expitope 3.0 at the 20th Annual Meeting of the Association for Cancer Immunotherapy (CIMT)

April 24, 2023

Medigene presents final Phase I data of TCR-T cell therapy MDG1011 in patients with high-risk blood cancers

April 18, 2023

New data presented at AACR shows enhanced T cell functionality of MDG1015 in solid tumors

April 11, 2023

Medigene to present Phase I clinical data for MDG1011 with poster presentation at EBMT 2023 Annual Meeting

April 4, 2023

Medigene AG Presents Systematic and Sequential, End-To-End Platform Approach to Optimize TCR-T Therapy Development

April 3, 2023

Medigene enters Cooperative Research and Development Agreement with the National Cancer Institute

March 29, 2023

Medigene AG Reports Full-Year 2022 Financial Results and Provides Corporate Update

March 28, 2023

Medigene AG to present at the 4th TCR-based Therapies for Solid Tumors Summit in Boston

March 20, 2023

Medigene AG Announces Appointment of Dr. Kirsty Crame, MD, as Head of Clinical Research & Development

March 16, 2023

Medigene to present first pre-clinical data for MDG1015 with poster presentation at AACR 2023 Annual Meeting

March 15, 2023

Medigene AG to report full year 2022 financial results on March 29, 2023

February 23, 2023

Medigene presents first results for automated manufacturing of T cell receptor engineered T cells

February 22, 2023

Medigene to participate in the H.C. Wainwright Cell Therapy Virtual Conference

February 15, 2023

Medigene to present at the 6th Annual CAR-TCR Summit Europe in London

February 1, 2023

Medigene AG Appoints Pamela Keck as Vice President of Investor Relations and Corporate Communications

January 18, 2023

Medigene Receives $3 Million Milestone Payment from 2seventy bio

November 21, 2023

Medigene amends 2023 financial guidance

March 10, 2023

Medigene amends 2022 financial guidance

January 31, 2023

Medigene adapts 2022 financial guidance